NIH Grant Made to Test BrainHQ Training Impact on Falls
October 12, 2021 08:00 ET
|
Posit Science
SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded a competitive grant to Posit Science, the maker of the...
Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate
October 07, 2021 11:00 ET
|
Tricol Biomedical
Portland, OR, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, has...
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
October 07, 2021 10:20 ET
|
Curative Biotechnology, Inc.
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Curative...
NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States
September 30, 2021 11:00 ET
|
AnaBios
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409...
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient
August 27, 2021 12:46 ET
|
BioAegis Therapeutics
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company...
Rendever Receives $2M NIH Phase II Grant to Further Research the Impact of Virtual Reality on the Aging Population
August 17, 2021 11:23 ET
|
Rendever
BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Rendever, a virtual reality (VR) platform built to help seniors overcome social isolation through shared experiences, today announces that it has been...
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
July 26, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat
June 17, 2021 05:00 ET
|
Rancho Santa Fe Bio
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) -- Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today...
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
June 07, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...